EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 7.28

Change

+1.34 (+22.56)%

Market Cap

N/A

Volume

5.39M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.34 (+1.74%)

USD 89.02B
HLN Haleon plc

N/A

USD 48.04B
TAK Takeda Pharmaceutical Co Ltd A..

+0.07 (+0.48%)

USD 47.42B
RDY Dr. Reddy’s Laboratories Ltd..

+0.42 (+0.53%)

USD 13.05B
CTLT Catalent Inc

+0.43 (+0.72%)

USD 10.91B
ELAN Elanco Animal Health

+0.07 (+0.51%)

USD 6.96B
BHC Bausch Health Companies Inc

+0.08 (+1.00%)

USD 2.98B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.01 (+0.12%)

USD 2.58B
CPHI China Pharma Holdings Inc

+0.03 (+12.55%)

USD 3.66M
YCBD cbdMD Inc

N/A

USD 1.73M

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 21.50 % 0.00 %

+0.55 (+1.47%)

USD 0.05B
XB4A:XETRA Xtrackers ATX UCITS ETF 1.. 21.50 % 0.00 %

+0.59 (+1.47%)

USD 0.05B
EXXX:XETRA iShares ATX UCITS ETF (DE.. 21.35 % 0.00 %

+0.30 (+1.47%)

USD 0.09B
EBNK:CA Evolve European Banks Enh.. 5.01 % 0.00 %

N/A

CAD 3.39M
IVES Amplify ETF Trust 3.51 % 0.00 %

+0.32 (+1.47%)

USD 0.02B
IS3H:XETRA iShares MSCI EMU Mid Cap .. 1.86 % 0.00 %

+0.64 (+1.47%)

USD 0.13B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.86 % 0.00 %

N/A

USD 0.13B
LDEU:LSE L&G Quality Equity Divide.. 1.39 % 0.00 %

+0.16 (+1.47%)

USD 0.04B
LGGE:XETRA L&G Quality Equity Divide.. 1.38 % 0.00 %

+0.18 (+1.47%)

USD 0.03B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+11.40 (+1.47%)

N/A
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.97 % 0.00 %

+0.14 (+1.47%)

USD 0.02B
EUMD:LSE iShares MSCI Europe Mid C.. 0.94 % 0.00 %

+0.08 (+1.47%)

USD 0.26B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.84 (+1.47%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 203.33% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 203.33% 100% F 100% F
Trailing 12 Months  
Capital Gain 119.94% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 119.94% 100% F 98% N/A
Trailing 5 Years  
Capital Gain -85.73% 23% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.73% 21% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -34.50% 6% D- 1% F
Dividend Return -34.50% 6% D- 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.71% 25% F 15% F
Risk Adjusted Return -61.92% 13% F 4% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector